Slideshows Images Quizzes

Climara Pro

Last reviewed on RxList: 11/15/2017
Climara Pro Side Effects Center

Last reviewed on RxList 11/15/2017

Climara Pro (estradiol/levonorgestrel) transdermal patch is a combination of female hormones used to treat menopause symptoms such as hot flashes, and to prevent osteoporosis (bone loss) in menopausal women. Climara Pro will not prevent dementia, heart attack, heart disease, or stroke. Common side effects of Climara Pro include patch application site reactions (skin redness, irritation, or skin rash), abdominal pain, nausea, vomiting, bloating, breast tenderness or swelling, headache, weight changes, swelling of the hands or feet, darkened spots on the skin of your face, contact lens discomfort, vaginal irritation or discomfort, depression, or changes in your menstrual periods.

A Climara Pro patch with a dose of 0.045 mg estradiol / 0.015 mg levonorgestrel (22 sq cm) is worn continuously on the lower abdomen. A new system should be applied weekly during a 28-day cycle. Climara Pro may interact with anticoagulants (blood thinners). Tell your doctor all medications and supplements you use. Climara Pro must not be used during pregnancy. If you become pregnant or think you may be pregnant, tell your doctor. This medication passes into breast milk. It may reduce the quality and amount of breast milk produced. Consult your doctor before breastfeeding.

Our Climara Pro (estradiol/levonorgestrel) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Climara Pro Consumer Information

Stop using this medication and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of the following serious side effects:

  • signs of a blood clot (sharp chest pain, coughing up blood, shortness of breath, pain in your calf);
  • signs of a heart attack (crushing chest pain, left-arm numbness);
  • signs of a stroke (sudden severe headache, problems with vision or speech, weakness, numbness);
  • nausea, stomach pain, low fever, lost appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or
  • new or changing breast lumps.

Other less serious side effects are more likely to occur, such as:

  • nausea and vomiting;
  • tender or swollen breasts;
  • swelling of the hands or feet;
  • darkened spots on the skin of your face;
  • contact lens discomfort;
  • vaginal irritation or discomfort;
  • headache, depressed mood;
  • a skin rash or reaction where the patch is worn; or
  • changes in your menstrual periods.

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Climara Pro (Estradiol, Levonorgestrel Transdermal)

Climara Pro Professional Information


The following serious adverse reactions are discussed elsewhere in the labeling:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described below is from a one-year, prospective, multicenter, double blind, double dummy, randomized, controlled trial investigating the effect of three different dosage combinations of E2/LNG versus E2 alone on the development of endometrial hyperplasia. All women were postmenopausal, had a serum estradiol level of less than 20 pg/mL, and the sample included both symptomatic and asymptomatic women. The data below includes all adverse reactions reported at a frequency of > 3% in the E2/LNG 0.045 / 0.015 group (the approved dosage for Climara Pro, N=212) and the E2 alone group (N=204).

Table 1: All Treatment Emergent Reactions Regardless of Relationship Reported at a Frequency of > 3% with Climara Pro in the 1-year Endometrial Hyperplasia Studya)

Body System Adverse Reaction Climara Pro 0.045 / 0.015
Na = 212
N = 204
Body as a Whole
  Abdominal pain 9 (4.2) 11 (5.4)
  Accidental injury 7 (3.3) 6 (2.9)
  Back pain 13 (6.1) 12 (5.9)
  Flu syndrome 10 (4.7) 13 (6.4)
  Infection 7 (3.3) 10 (4.9)
  Pain 11 (5.2) 13 (6.4)
Cardiovascular System
  Hypertension 7 (3.3) 9 (4.4)
Digestive System
  Flatulence 8 (3.8) 11 (5.4)
Metabolic and Nutritional  
  Edema 8 (3.8) 5 (2.5)
  Weight gain 6 (2.8) 10 (4.9)
Musculoskeletal System
  Arthralgia 9 (4.2) 10 (4.9)
Nervous System
  Depression 12 (5.7) 7 (3.4)
  Headache 11 (5.2) 14 (6.9)
Respiratory System
  Bronchitis 9 (4.2) 7 (3.4)
  Sinusitis 8 (3.8) 12 (5.9)
  Upper respiratory infection 28 (13.2) 26 (12.7)
Skin and Appendages
  Application site reaction 86 (40.6) 69 (33.8)
  Breast pain 40 (18.9) 20 (9.8)
  Rash 5 (2.4) 10 (4.9)
Urogenital System
  Urinary Tract Infection 7 (3.3) 8 (3.9)
  Vaginal Bleeding 78 (36.8) 44 (21.6)
  Vaginitis 4 (1.9) 6 (2.9)
aN = total number of subjects in a treatment group; n = number of subjects with event.

Irritation potential of Climara Pro was assessed in a 3-week irritation study. The study compared the irritation of a Climara Pro placebo patch (22 cm²) to a placebo (25 cm²). Visual assessments of irritation were made on Day 7 of each wear period, approximately 30 minutes after patch removal using a 7-point scale (0 = no evidence of irritation; 1 = minimal erythema, barely perceptible; 2 = definite erythema, readily visible, or minimal edema, or minimal papular response; 3-7 = erythema and papules, edema, vesicles, strong extensive reaction).

The mean irritation scores were 0.13 (week 1), 0.12 (week 2), and 0.06 (week 3) for the Climara Pro placebo. The mean scores for the Climara placebo were 0.2 (week 1), 0.26 (week 2), 0.12 (week 3). There were no irritation scores greater than 2 at any timepoint in any subject.

In controlled clinical trials, withdrawals due to application site reactions occurred in 6 (2.1 percent) of subjects in the 12week symptom study and in 71 (8.5 percent) of subjects in the 1-year endometrial protection study.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of the Climara Pro transdermal system. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Genitourinary System

Changes in bleeding patterns


Abdominal distension,* abdominal pain,* nausea


Alopecia, night sweats, pruritus,* Rash,* hot flush*

Central Nervous System

Dizziness, headache, insomnia


Application site reaction,* weight increased, anaphylactic reaction

* Combined two or more similar ARs

Read the entire FDA prescribing information for Climara Pro (Estradiol, Levonorgestrel Transdermal)

Related Resources for Climara Pro

Read the Climara Pro User Reviews »

© Climara Pro Patient Information is supplied by Cerner Multum, Inc. and Climara Pro Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors